QTREX Quantum Ltd. QTEX
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
QTREX Quantum Ltd. (QTEX) is a healthcare company listed in the US with a market value of about $70M. In fiscal year 2025 it had revenue of $289000 and net income of -$13M, a net margin of -4574.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -204%.
About QTREX Quantum
QTREX Quantum is listed in the US and classified in medical/dental instruments, IPO year 2021. It was profitable in 1 of the last 7 years in our data. It spends 2594% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $289000 | $0 | $0 | — | — | — | — |
| Net income | -$13M | -$11M | -$11M | -$15M | -$17M | $17M | -$5M |
| Free cash flow | -$10M | -$10M | -$10M | -$9M | -$7M | -$2M | -$1M |
| EPS (diluted) | $-0.24 | $-0.20 | $-0.20 | $-0.27 | $-0.31 | $0.30 | $-0.08 |
| Net margin | -4574.4% | — | — | — | — | — | — |
| ROIC | -486.0% | -226.4% | -183.4% | -79.7% | -43.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does QTREX Quantum pay a dividend?
Not currently.
Is QTREX Quantum a good stock to buy?
We do not give buy or sell advice. QTREX Quantum scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.